Specifically, the increased expression of MGAT5 in RA may lead to the production of N-glycans with more branched structures, which in turn may enhance the binding of immune cells to inflammatory molecules, such as cytokines and chemokines, leading to increased inflammation and joint damage.” On closer examination, the references do not exist, and the specific statements made are generally not supported specifically in RA, but rather the statements generalise across a range of IMIDS including SLE and MS. Here, MGAT5 is linked to myeloid sarcoma.